As such, most patients with high-risk or node-positive HER2+ breast cancer are treated with neoadjuvant chemotherapy plus dual HER2 blockade with trastuzumab and pertuzumab regardless of estrogen receptor (ER) status. This evidence concerns the gene ERBB2 and breast carcinoma.